Enlivex Therapeutics Ltd.
Tel Aviv Stock Exchange ENLV.TA
Enlivex Therapeutics Ltd. Gross Profit for the year ending December 31, 2023: USD 0.00
Enlivex Therapeutics Ltd. Gross Profit is USD 0.00 for the year ending December 31, 2023, a 0.00% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.
-
Enlivex Therapeutics Ltd. Gross Profit for the year ending December 31, 2022 was USD 0.00, a 0.00% change year over year.
-
Enlivex Therapeutics Ltd. Gross Profit for the year ending December 31, 2021 was USD 0.00, a 0.00% change year over year.
-
Enlivex Therapeutics Ltd. Gross Profit for the year ending December 31, 2020 was USD 0.00, a 0.00% change year over year.
-
Enlivex Therapeutics Ltd. Gross Profit for the year ending December 31, 2019 was USD 0.00, a 0.00% change year over year.
Key data
| Date | Gross Profit | Operating Income | EBIT | EBITDA |
|---|
Market news
Loading...
Tel Aviv Stock Exchange: ENLV.TA
| CEO | Dr. Oren Hershkovitz Ph.D. |
| IPO Date | July 22, 2019 |
| Location | Israel |
| Headquarters | 14 Einstein Street |
| Employees | 77 |
| Sector | Health Care |
| Industries | |
Description
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email